Daxas roflumilast: Additional Phase III data

Additional data from the double-blind, international Phase III HERMES trial in 1,568 patients showed that that once-daily 500 ug oral Daxas for 52 weeks significantly improved mean pre-bronchodilator FEV1 by 58 mL vs.

Read the full 332 word article

User Sign In